penpulimab   Click here for help

GtoPdb Ligand ID: 12347

Synonyms: AK-105 | AK105
Approved drug Immunopharmacology Ligand
penpulimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Penpulimab (AK-105) is a chimeric IgG1κ programmed cell death 1 (PD-1) monoclonal antibody [2]. Its engineered Fc structure means that it does not interact with Fcγ receptors and therefore it does not induce immune cell (macrophage) effector functions (antibody-dependent cell-mediated cytotoxicity/ADCC, antibody-dependent cellular phagocytosis/ADCP, antibody-dependent cytokine release/ADCR). Penpulimab binds to an epitope in human PD-1's N-glycosylation site (at residue N58).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (China (2021))
Approved drug? Yes. China (2021)
International Nonproprietary Names Click here for help
INN number INN
11497 penpulimab
Synonyms Click here for help
AK-105 | AK105
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1093
Other databases
GtoPdb PubChem SID 479821138
Search PubMed clinical trials penpulimab
Search PubMed titles penpulimab
Search PubMed titles/abstracts penpulimab